Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 20/20 | 0.92 |
| ▸ | CSNK2B | P67870 | 20/20 | 0.92 |
| ▸ | CSNK2A2 | P19784 | 17/20 | 0.92 |
| ▸ | PIM3 | Q86V86 | 17/20 | 0.92 |
| ▸ | PIM2 | Q9P1W9 | 17/20 | 0.92 |
| ▸ | CDC7 | O00311 | 8/20 | 0.83 |
| ▸ | CSNK2A1 | P68400 | 8/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852333 | 0.96 | PIM1 (1.00) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL1850003 | 0.93 | PIM1 (1.00) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL1850218 | 0.91 | PIM1 (1.00) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL1851443 | 0.90 | PIM1 (1.00) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL12661367 | 0.88 | PIM1 (0.72) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL1849040 | 0.88 | PIM1 (0.84) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL1852627 | 0.87 | PIM1 (0.82) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL1850272 | 0.86 | PIM1 (0.81) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL1852607 | 0.86 | PIM1 (0.81) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL1851785 | 0.85 | PIM1 (0.80) | PIM1CSNK2BCSNK2A2PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | claimed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | PIM1 1977/4885CSNK2B 350/4885CSNK2A2 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.